Yes, pulmonary hypertension can be treated, but there is no single cure suitable for everyone. Treatment depends primarily on the cause. Some forms can improve substantially when the underlying disease is corrected; others require specific long-term therapies. In pulmonary arterial hypertension, medications are available that slow progression and reduce the risk of deterioration, while in chronic thromboembolic pulmonary hypertension, procedures are also available that may potentially be curative in suitable patients.
Therefore, the crucial issue is not simply "lowering pulmonary pressure", but understanding which type of pulmonary hypertension is present.
Treatment is selected after establishing the clinical group, severity, right ventricular function, comorbidities and, where appropriate, risk profile. Medications specific to pulmonary arterial hypertension must not be regarded as generic treatment for "high blood pressure in the lungs".
The main points to understand are:
Response varies according to the cause. In pulmonary arterial hypertension , modern treatment can improve symptoms, exercise capacity, hemodynamics and prognosis, but the condition remains chronic in most cases and requires ongoing treatment and monitoring.
In some secondary forms, however, effectively treating the cause can also reduce the pulmonary component. This may occur, for example, in certain valvular disorders or left heart conditions when the responsible problem is corrected, although advanced pulmonary vascular damage may not regress completely.
A particularly distinct situation is chronic thromboembolic pulmonary hypertension. In patients whose disease is technically operable and whose clinical condition is compatible with surgery, pulmonary endarterectomy removes organized fibrotic material from the pulmonary arteries and offers a potentially curative treatment. When surgery is not possible, or residual pulmonary hypertension persists, balloon pulmonary angioplasty and selected medical therapies may be used.
In PAH, the modern strategy is based on combining several therapies and reassessing the response early. Available medications target four major biological pathways: endothelin, nitric oxide, prostacyclin and activin/BMP signaling. Classes used include endothelin receptor antagonists, phosphodiesterase type 5 inhibitors, soluble guanylate cyclase stimulators, prostacyclin analogues, prostacyclin receptor agonists and sotatercept.
Treatment choice is not based on a simple list of medications, but on disease severity, risk, comorbidities, contraindications and the response achieved.
In selected settings, patients with idiopathic, heritable or medication-associated PAH undergo acute vasoreactivity testing during right heart catheterization. Only a small proportion show a suitable acute response and may be candidates for high-dose calcium channel blocker therapy under close specialist supervision. These medications must not be used empirically in patients without demonstrated appropriate vasoreactivity.
PAH treatment has progressively become more intensive. For many patients without major cardiopulmonary comorbidities, initial combination oral therapy is recommended; high-risk presentations may require regimens including parenteral prostacyclins. The 7th World Symposium on Pulmonary Hypertension has also incorporated the activin/BMP pathway among therapeutic targets.
The ERS guideline update published in September 2026 recommends sotatercept as add-on therapy for patients with PAH who are already receiving specific medications and remain at intermediate-low, intermediate-high or high risk at follow-up. No recommendation was made for patients already at low risk because the available evidence remains insufficient. Sotatercept treatment must be managed at expert pulmonary hypertension centers with regular efficacy and safety monitoring.
In pulmonary hypertension due to left heart disease , the primary treatment targets the underlying cardiac condition. Diuretics may be required in the presence of congestion, alongside therapies recommended for heart failure or valvular disease according to the specific circumstances. Medications approved for PAH are not standard treatment for this group, and some may be ineffective or harmful.
In pulmonary hypertension associated with lung disease , the priority is to optimize treatment of the respiratory condition, correct hypoxemia when indicated and arrange specialist assessment when pulmonary hypertension is substantial or disproportionate to the lung disease. In selected situations, particularly pulmonary hypertension associated with interstitial lung disease, specific treatment options are available, but PAH therapies cannot automatically be extended to every group 3 form.
This is one reason why a diagnosis based solely on echocardiography is insufficient for treatment decisions. Before prescribing specific medications, the hemodynamic mechanism and predominant cause must be established.
Beyond treatments targeting the cause, many patients may need supportive measures. Diuretics are used when fluid retention, edema or congestion due to right ventricular failure develops. Oxygen therapy is indicated when hypoxemia meets specific clinical criteria; it is not prescribed merely because pulmonary hypertension is present.
Anticoagulation is not universally required for all forms of pulmonary hypertension. It is essential in chronic thromboembolic disease and may be indicated for other reasons, but in PAH the decision depends on the subtype and individual profile.
Management also includes appropriate vaccinations, treatment of anemia and iron deficiency when present, adapted physical activity and rehabilitation programs in clinically stable patients, attention to pregnancy and contraception in people at risk, travel planning and psychological support when needed. These measures do not replace specific treatment but contribute to safety and quality of life.
In PAH, it is not enough to check whether a patient "feels a little better". Follow-up integrates symptoms, functional class, 6-minute walk distance, BNP or NT-proBNP, echocardiography and, when necessary, other imaging tests or hemodynamic parameters. The aim is to achieve and maintain a low-risk profile, because residual risk is closely linked to prognosis.
The 2026 ERS update also suggests repeat right heart catheterization during follow-up in treated patients who remain at intermediate-low, intermediate-high or high risk when the result could meaningfully change treatment strategy. If the response is inadequate, treatment is intensified. In patients with advanced disease despite optimal therapy, referral for lung transplantation assessment should also be considered promptly.
Pulmonary hypertension treatment is therefore dynamic: initial therapy is only the beginning of the pathway. Response during the first months, right ventricular changes and any emergence of high-risk signs guide subsequent decisions.
Can pulmonary hypertension be completely cured?
It depends on the cause. Some forms can improve substantially when the underlying disease is treated, and CTEPH may potentially be cured by pulmonary endarterectomy in operable patients. Pulmonary arterial hypertension, by contrast, is generally a chronic condition that can be treated but not definitively cured with available medications.
Is there a single medication for every form of pulmonary hypertension?
No. Medications specific to pulmonary arterial hypertension are not automatically indicated for forms caused by left heart disease, lung diseases or other conditions.
Which medications are used for pulmonary arterial hypertension?
Therapies may target the endothelin, nitric oxide, prostacyclin and activin/BMP signaling pathways. Choice and combinations depend on the patient's profile and risk.
Can chronic thromboembolic pulmonary hypertension be treated surgically?
Yes. In operable CTEPH, pulmonary endarterectomy is the treatment of choice and can potentially be curative. Other options, including balloon pulmonary angioplasty and medical treatment, are available for inoperable cases or residual disease.
How can treatment effectiveness be assessed?
Response is assessed over time using symptoms, functional class, exercise capacity, BNP or NT-proBNP, echocardiography, hemodynamic measurements and other risk indicators. In PAH, the goal is to achieve and maintain a low-risk profile.
Informational notice: the information contained on this page is provided solely for informational and educational purposes and does not replace the advice, diagnosis or treatment provided by a physician. If needed, always consult a qualified healthcare professional.
Artificial intelligence transparency: this page was created with the support of artificial intelligence tools, used to assist in the production and processing of its content.